Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Cisplatin + GL-ONC1 + Radiotherapy|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cisplatin||Platinol||CDDP||Chemotherapy - Platinum 6||Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary).|
|GL-ONC1||GL-ONC1 is a genetically engineered oncolytic vaccinia virus, which results in viral infection within the cells, thereby possibly inducing cell death and interruption of the cell cycle (PMID: 28679776).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||head and neck cancer||not applicable||Cisplatin + GL-ONC1 + Radiotherapy||Phase I||Actionable||In a Phase I trial, the combination therapy of GL-ONC1, Platinol (cisplatin), and radiotherapy resulted in a progression-free survival of 74.4% at 1 year and 64.1% at 2 years and an overall survival of 84.6% at 1 year and 69.2% at 2 years in patients with nonmetastatic head and neck cancer (PMID: 28679776).||28679776|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|